CRISPR-Based Diagnostics Market Report 2026

The crispr-based diagnostics market size has grown rapidly in recent years. It will grow from $5.1 billion in 2025 to $6.01 billion in 2026 at a compound annual growth rate (CAGR) of 17.8%. The growth in the historic period can be attributed to need for rapid and accurate diagnostics, limitations of traditional molecular tests, pandemic-driven diagnostic demand, advancements in crispr detection methods, academic validation of crispr diagnostics.

The crispr-based diagnostics market size is expected to see rapid growth in the next few years. It will grow to $11.45 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to growth of decentralized testing models, rising demand for early disease detection, expansion of point-of-care diagnostics, integration with digital health platforms, increasing adoption in oncology and genetic screening. Major trends in the forecast period include rising adoption of rapid molecular diagnostics, expansion of point-of-care testing solutions, increased use in infectious disease detection, integration with isothermal amplification techniques, growth of personalized diagnostic applications.

The increasing incidence of infectious diseases is expected to drive the growth of the CRISPR-based diagnostics market in the coming years. Infectious diseases are conditions caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, which can spread directly or indirectly through person-to-person contact, contaminated surfaces, food, water, or vectors such as insects. The rise in infectious diseases is attributed to factors such as globalization, antibiotic resistance, climate change, urbanization, population growth, habitat destruction, and limited access to healthcare. CRISPR-based diagnostics support the management of infectious diseases by enabling rapid and accurate pathogen detection, which allows for early diagnosis, timely treatment, and effective containment strategies. For example, in August 2024, according to data released by the UK Health Security Agency, a UK-based executive agency, 368 measles cases were reported in England in 2023, representing nearly a sevenfold increase compared to the 53 cases recorded in 2022. The West Midlands and London accounted for 44 percent and 33 percent of the cases, respectively. Therefore, the growing incidence of infectious diseases is contributing to the expansion of the CRISPR-based diagnostics market.

Major companies operating in the CRISPR-based diagnostics market are increasingly focusing on forming strategic partnerships to improve accessibility to fast and accurate diagnostic solutions through CRISPR-based point-of-care tests. A strategic partnership is a long-term collaboration between organizations that combine resources and expertise to achieve shared objectives and strengthen their market position. For instance, in August 2023, CrisprBits Private Limited, an India-based biotechnology company, announced a strategic collaboration with Molbio Diagnostics, an India-based molecular diagnostics firm, to develop CRISPR-based point-of-care tests. This collaboration is aimed at creating rapid, precise, and cost-effective diagnostic tools using CRISPR technology to detect pathogens and genetic markers. These point-of-care tests are designed to improve diagnostic access across diverse environments, including resource-constrained settings, while ensuring quick and accurate disease detection. The partnership leverages CrisprBits’ CRISPR platform expertise and Molbio’s manufacturing and distribution capabilities to enable global deployment of these diagnostic solutions.

In February 2024, Ginkgo Bioworks Holdings Inc., a US-based biotechnology company, acquired Proof Diagnostics Inc. for an undisclosed amount. Through this acquisition, Ginkgo aims to strengthen its gene therapy services by integrating Proof Diagnostics’ OMEGA RNA-programmable nuclease technology and enhancing its gene-editing capabilities. This acquisition supports Ginkgo’s ability to deliver advanced solutions in therapeutic development and precision gene editing. Proof Diagnostics Inc. is a US-based company specializing in CRISPR-based molecular testing solutions for COVID-19.

Major companies operating in the crispr-based diagnostics market are Thermo Fisher Scientific Inc., Integrated DNA Technologies Inc., Molbio Diagnostics, Horizon Discovery, Synthego Corporation, Caribou Biosciences, Mammoth Biosciences, Epic Bio, VedaBio, CrisprBits, SNIPR BIOME ApS, TOLO Biotech, Intact Genomics, Agdia Inc., ToolGen Inc., Caspr Biotech, GenScript, Twist Bioscience, Revvity Discovery Limited, Danaher Corporation, Scope Biosciences, CRISPR Diagnostics, Gene Editing Institute, Aptitude Medical Systems, Qiagen, Abingdon Health.

North America was the largest region in the CRISPR-based diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crispr-based diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the crispr-based diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the crispr-based diagnostics market by increasing costs of imported diagnostic kits, enzymes, buffers, reagents, and analytical instruments. Hospitals and diagnostic centers in North America and Europe are most affected due to dependence on imported consumables, while Asia-Pacific faces higher setup costs for diagnostic infrastructure. These tariffs are increasing testing expenses. However, they are also encouraging local kit manufacturing, domestic diagnostic innovation, and improved supply chain resilience.

The crispr-based diagnostics market research report is one of a series of new reports that provides crispr-based diagnostics market statistics, including crispr-based diagnostics industry global market size, regional shares, competitors with a crispr-based diagnostics market share, detailed crispr-based diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the crispr-based diagnostics industry. This crispr-based diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

CRISPR-based diagnostics refer to advanced molecular tools that use the CRISPR-Cas system to identify specific nucleic acid sequences with high accuracy and speed for the detection of diseases or genetic markers. These diagnostics provide transformative capabilities in medical and genomic analysis and are used in applications such as the detection of infectious diseases, identification of genetic disorders, and monitoring of mutations in cancer research and treatment. They also hold increasing potential in personalized medicine and point-of-care testing.

The primary products in the CRISPR-based diagnostics market include kits, buffer solutions, software, and other related products. Diagnostic kits are ready-to-use solutions designed to enable rapid and precise detection of targeted genetic material using CRISPR technology, and are widely applied in both disease diagnosis and research. The techniques employed in CRISPR-based diagnostics include recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), and other methods. These diagnostics are used for both infectious and non-infectious diseases and are adopted by end users such as hospitals, diagnostic centers, biotechnology companies, and academic and research institutions.

The CRISPR-based diagnostics market includes revenues earned by entities by providing services such as diagnostic testing services, custom CRISPR assays development, screening and surveillance services, and regulatory and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR-based diagnostics market also consists of sales of CRISPR-based RNA detection systems, CRISPR-based monitoring tools, lateral flow assays, and CRISPR-based test platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.